Targeting renal damage: The ACE2/Ang-(1–7)/mas axis in chronic kidney disease.

The renin–angiotensin system (RAS) is a crucial factor in chronic kidney disease (CKD) progression, affecting renal function and contributing significantly to renal tissue inflammation and fibrosis. Activation of the classical ACE/Ang II/AT1 axis exacerbates renal damage, while the ACE2/Ang-(1–7)/Mas axis has shown promise in reducing CKD progression in numerous animal models. Recently, the ACE2/Ang-(1–7)/Mas axis has emerged as a promising target for CKD interventions. This review provides a comprehensive review of the pivotal role of this axis in CKD pathogenesis and systematically examines various molecules and pharmaceutical agents targeting this pathway. This review aims to elucidate potential strategies for delaying or halting CKD progression, offering patients more effective treatment options. • The ACE2/Ang-(1–7)/MasR axis shows renoprotection, contrasting classical RAS. • The ACE2/Ang-(1–7)/MasR axis curbs inflammation and fibrosis, slowing CKD progression. • Targeting the ACE2/Ang-(1–7)/MasR axis in CKD treatment is a promising strategy. [ABSTRACT FROM AUTHOR]